PTC Therapeutics, Inc. (PTCT) financial statements and ratios from SEC XBRL: revenue $1.0B (TTM), net margin 39.4%, revenue growth 101.5% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $1.73B |
| Revenue (TTM) | $1.0B |
| Net Margin | 39.4% |
| Operating Margin (TTM) | 12.5% |
| Net Debt / EBITDA | -2.4 |
| Revenue Growth (YoY) | 101.5% |
| EPS Growth (YoY) | -221.7% |
| FCF Growth (YoY) | -312.8% |
| EV / EBITDA | 29.6 |
| Price / Sales | 5.78 |
| FCF Yield | -0.7% |
| Altman Z-Score | 1.81 (grey) |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Sector P/E (Healthcare) | 21.7 |
PTCT overview · PTCT earnings · PTCT KPIs · PTCT documents · PTCT ownership · PTCT peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.